Durable Response in NTRK Fusion-Positive Advanced Salivary Gland Tumor: A Case Report

NTRK fusions lead to the production of constitutively active TRK proteins, which drive oncogenesis in approximately 0.2% of cancers. However, these fusions occur more frequently in salivary gland-type tumors, making them a promising therapeutic target in patients with advanced disease. Recent studies have shown that TRK inhibitors, such as entrectinib, larotrectinib and repotrectinib, are effective in treating solid tumors harboring NTRK gene fusions. This underscores the importance of incorporating comprehensive molecular profiling in these tumors to identify actionable biomarkers and broaden treatment options.

Here, we present the clinical journey of a patient diagnosed with unresectable salivary gland carcinoma that was refractory to both local and systemic treatments. Following molecular profiling, NTRK targeted therapy was initiated, resulting in a significant and sustained response.

To our knowledge, this is the first reported case in Bolivia of a salivary gland tumor with an NTRK fusion identified through molecular profiling, followed by successful treatment with compassionate use of entrectinib. This case not only demonstrates the therapeutic benefits and safety of NTRK inhibitors but also underscores the importance of personalized therapy guided by molecular profiling in oncology.